Morgan Stanley
IBIO icon

Morgan Stanley’s iBio IBIO Stock Holding History

Morgan Stanley’s Portfolio IBIO Stock Details IBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18 Sell
10
-30,927
-100% -$55.3K ﹤0.01% 8298
2026
Q1 		$58.8K Buy
30,937
+3,342
+12% +$7.75K ﹤0.01% 6362
2025
Q4 		$53.3K Buy
27,595
+27,538
+48,312% +$37.6K ﹤0.01% 6413
2025
Q3 		$47 Buy
57
+8
+16% +$6 ﹤0.01% 7866
2025
Q2 		$38 Sell
49
-3,726
-99% -$4.04K ﹤0.01% 7867
2025
Q1 		$15.2K Buy
3,775
+3,727
+7,765% +$14.5K ﹤0.01% 6660
2024
Q4 		$117 Hold
48
– – ﹤0.01% 7454
2024
Q3 		$107 Sell
48
-1
-2% -$2 ﹤0.01% 7432
2024
Q2 		$103 Sell
49
-219
-82% -$471 ﹤0.01% 7345
2024
Q1 		$1.09K Sell
268
-71
-21% -$89 ﹤0.01% 7164
2023
Q4 		$464 Sell
339
-24
-7% -$105 ﹤0.01% 7213
2023
Q3 		$2.2K Buy
363
+5
+1% +$43 ﹤0.01% 7109
2023
Q2 		$4.36K Buy
358
+256
+251% +$4.83K ﹤0.01% 7017
2023
Q1 		$4.23K Sell
102
-255
-71% -$6.56K ﹤0.01% 7091
2022
Q4 		$3.17K Buy
357
+234
+190% +$7.92K ﹤0.01% 7258
2022
Q3 		$11K Sell
123
-544
-82% -$74.9K ﹤0.01% 7040
2022
Q2 		$88K Buy
667
+363
+119% +$54.6K ﹤0.01% 6344
2022
Q1 		$64K Sell
304
-15
-5% -$3.14K ﹤0.01% 6575
2021
Q4 		$86K Buy
319
+58
+22% +$22.1K ﹤0.01% 6527
2021
Q3 		$138K Sell
261
-64
-20% -$39.9K ﹤0.01% 6193
2021
Q2 		$244K Buy
325
+116
+56% +$84.6K ﹤0.01% 5911
2021
Q1 		$161K Sell
209
-406
-66% -$354K ﹤0.01% 5776
2020
Q4 		$323K Sell
615
-6
-1% -$4.89K ﹤0.01% 5329
2020
Q3 		$631K Buy
621
+561
+935% +$813K ﹤0.01% 4517
2020
Q2 		$67K Buy
60
+53
+757% +$34.7K ﹤0.01% 5567
2020
Q1 		$4K Buy
7
+5
+250% +$1.92K ﹤0.01% 6268
2019
Q4 		$0 Sell
2
-1
-33% -$136 ﹤0.01% 6692
2019
Q3 		$1K Hold
3
– – ﹤0.01% 6545
2019
Q2 		$1K Hold
3
– – ﹤0.01% 6542
2019
Q1 		$1K Hold
3
– – ﹤0.01% 6514
2018
Q4 		$1K Hold
3
– – ﹤0.01% 6501
2018
Q3 		$1K Hold
3
– – ﹤0.01% 6625
2018
Q2 		$1K Hold
3
– – ﹤0.01% 6589
2018
Q1 		$3K Hold
3
– – ﹤0.01% 6453
2017
Q4 		$3K Hold
3
– – ﹤0.01% 6397
2017
Q3 		$5K Hold
3
– – ﹤0.01% 6290
2017
Q2 		$7K Buy
3
+1
+50% +$1.96K ﹤0.01% 6300
2017
Q1 		$4K Hold
2
– – ﹤0.01% 6383
2016
Q4 		$4K Hold
2
– – ﹤0.01% 6301
2016
Q3 		$6K Hold
2
– – ﹤0.01% 6200
2016
Q2 		$9K Hold
2
– – ﹤0.01% 6082
2016
Q1 		$7K Hold
2
– – ﹤0.01% 6209
2015
Q4 		$6K Sell
2
-1
-33% -$3.19K ﹤0.01% 6342
2015
Q3 		$10K Hold
3
– – ﹤0.01% 6237
2015
Q2 		$14K Buy
3
+2
+200% +$9.3K ﹤0.01% 6219
2015
Q1 		$5K Hold
1
– – ﹤0.01% 6339
2014
Q4 		$4K Buy
+1
New +$5.34K ﹤0.01% 6367
2014
Q3 		– Sell
-1
Closed -$2K – 6604
2014
Q2 		$2K Sell
1
-1
-50% -$2.16K ﹤0.01% 6386
2014
Q1 		$5K Hold
2
– – ﹤0.01% 6244
2013
Q4 		$3K Buy
+2
New +$3.64K ﹤0.01% 6217

Other funds holding IBIO

AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Morgan Stanley's IBIO Position: Q2 2026 in Review

Morgan Stanley reduced its iBio (IBIO) stake by 100% in Q2 2026, selling an estimated $55.3K and leaving 10 shares worth $18. The position accounts for ﹤0.01% of the portfolio, ranked #8298.

Morgan Stanley first reported a position in IBIO in Q4 2013 and has held it in 50 quarters since. The position peaked at $631K in Q3 2020. 55 funds tracked by Wall St. Rank hold IBIO as of Q2 2026.

  • Morgan Stanley held 10 shares of iBio worth $18 as of Q2 2026.
  • Morgan Stanley sold 30,927 iBio shares in Q2 2026, an estimated $55.3K.
  • iBio made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #8298 holding.
  • Morgan Stanley first reported a position in iBio in Q4 2013 and has held it in 50 quarters since.
  • Morgan Stanley's iBio position peaked at $631K in Q3 2020.
  • 55 funds tracked by Wall St. Rank held iBio as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.